article · Expert Opinion on Drug Safety
BACKGROUND: The aim of our study was to determine the prevalence of hypersensitivity reactions in patients with chronic rheumatic diseases (CRD) treated with biologic therapies, and to evaluate the associated factors. RESEARCH DESIGN AND METHODS: A 6-year retrospective, single-center study was performed, including patients with CRD treated with biologic therapies. RESULTS: = 0.01). CONCLUSIONS: Considering the predictive factors of hypersensitivity reactions to biologics in clinical practice could help anticipate risks and improve patient safety.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1080/14740338.2025.2567588
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
